Main characteristics of active and inactive CSS, atopic, and HES patients
| . | Active CSS (n = 6) . | Inactive CSS (n = 13) . | Atopic patients (n = 8) . | Undefined HES patients (n = 15) . |
|---|---|---|---|---|
| Demography | ||||
| Median age, years (range) | 63 (54-74) | 61 (18-76) | 44 (31-63) | 46 (23-79) |
| Female sex, n (%) | 1 (17) | 10 (77) | 5 (63) | 6 (40) |
| Clinical features | ||||
| General signs, n (%) | 6 (100) | 0 (0) | 0 (0) | 2 (13) |
| Asthma, n (%) | 6 (100) | 0 (0) | 5 (74) | 1 (7) |
| Arthralgias, n (%) | 1 (17) | 0 (0) | 0 (0) | 1 (7) |
| Myalgias, n (%) | 2 (33) | 0 (0) | 0 (0) | 0 (0) |
| Rhinitis/Sinusitis, n (%) | 4 (67) | 0 (0) | 3 (26) | 2 (13) |
| Active neuropathy, n (%) | 6 (100) | 0 (0) | 0 (0) | 1 (7) |
| Pulmonary infiltrates, n (%) | 1 (17 | 0 (0) | 0 (0) | 2 (15) |
| Cardiopathy, n (%) | 2 (33) | 0 (0) | 0 (0) | 0 (0) |
| Cutaneous, n (%) | 0 (0) | 0 (0) | 0 (0) | 5 (33) |
| Gastrointestinal, n (%) | 1 (17) | 0 (0) | 0 (0) | 4 (27) |
| BVAS, median (range) | 17 (14-27) | 0 (0) | NR | NR |
| Laboratory features | ||||
| Eosinophil count, per mm3, median | 9250 | 175 | 130 | 2550 |
| Range | (530-19 350) | (0-790) | (33-908) | (1500-13 800) |
| pANCA*, n (%) | 6 (100) | 8 (62) | NR | NR |
| Treatments | ||||
| Prednisone, n (%) | 0 (0) | 13 (100) | 0 (0) | 0 (0) |
| Prednisone dosage, median (range), mg/d | NR | 20 (5-50) | NR | NR |
| Immunosuppressant agents, n (%) | 0 (0) | 5 (38) | NR | 0 (0) |
| . | Active CSS (n = 6) . | Inactive CSS (n = 13) . | Atopic patients (n = 8) . | Undefined HES patients (n = 15) . |
|---|---|---|---|---|
| Demography | ||||
| Median age, years (range) | 63 (54-74) | 61 (18-76) | 44 (31-63) | 46 (23-79) |
| Female sex, n (%) | 1 (17) | 10 (77) | 5 (63) | 6 (40) |
| Clinical features | ||||
| General signs, n (%) | 6 (100) | 0 (0) | 0 (0) | 2 (13) |
| Asthma, n (%) | 6 (100) | 0 (0) | 5 (74) | 1 (7) |
| Arthralgias, n (%) | 1 (17) | 0 (0) | 0 (0) | 1 (7) |
| Myalgias, n (%) | 2 (33) | 0 (0) | 0 (0) | 0 (0) |
| Rhinitis/Sinusitis, n (%) | 4 (67) | 0 (0) | 3 (26) | 2 (13) |
| Active neuropathy, n (%) | 6 (100) | 0 (0) | 0 (0) | 1 (7) |
| Pulmonary infiltrates, n (%) | 1 (17 | 0 (0) | 0 (0) | 2 (15) |
| Cardiopathy, n (%) | 2 (33) | 0 (0) | 0 (0) | 0 (0) |
| Cutaneous, n (%) | 0 (0) | 0 (0) | 0 (0) | 5 (33) |
| Gastrointestinal, n (%) | 1 (17) | 0 (0) | 0 (0) | 4 (27) |
| BVAS, median (range) | 17 (14-27) | 0 (0) | NR | NR |
| Laboratory features | ||||
| Eosinophil count, per mm3, median | 9250 | 175 | 130 | 2550 |
| Range | (530-19 350) | (0-790) | (33-908) | (1500-13 800) |
| pANCA*, n (%) | 6 (100) | 8 (62) | NR | NR |
| Treatments | ||||
| Prednisone, n (%) | 0 (0) | 13 (100) | 0 (0) | 0 (0) |
| Prednisone dosage, median (range), mg/d | NR | 20 (5-50) | NR | NR |
| Immunosuppressant agents, n (%) | 0 (0) | 5 (38) | NR | 0 (0) |
Perinuclear anti-neutrophil cytoplasmic antibody with anti-myeloperoxydase specificity.
General signs are defined as weight loss > 10%, fever and/or night sweats. NR indicates not relevant.